HIV and Non-communicable Diseases Pre-Conference, July 15-16, 2011, Rome Gaps in Knowledge, and Future Research Priorities in LMIC NCD Risk in PLWH 1.What.

Slides:



Advertisements
Similar presentations
Type 2 diabetes Implementing NICE guidance 2009 NICE clinical guideline 87.
Advertisements

10 Points to Remember for the Management of Overweight and Obesity in Adults Management of Overweight and Obesity in Adults Summary Prepared by Elizabeth.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
ECONOMIC ASSESSMENT OF IMPLEMENTATION TREATMENT GUIDELINES OF HYPERTENSION IN OUT-PATIENT PRACTICE Kulmagambetov IR Karaganda State Medical Academy, Kazakhstan.
CVD risk estimation and prevention: An overview of SIGN 97.
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Obesity Treatment in Special Populations
Module 7: Malaria and HIV/AIDS Palliative Care for People Living with HIV/AIDS.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Understanding blood lipids and glucose How a Healthy Lifestyle can improve your numbers Susan Fullmer, PhD RD Associate Teaching Professor Nutrition, Dietetics,
CONGESTIVE HEART FAILURE By: Sade Jordan Donisha Grier.
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Professor Julia Hippisley-Cox University of Nottingham.
Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.
Establishing Preventive Cardiology Programs Nathan Wong Nathan Wong.
Fetal Origins of Disease Hypothesis Grace M. Egeland, Ph.D. University of Bergen.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.
1FHI 360 Nigeria. 2USAID Nigeria
Improving the Quality of Physical Health Checks
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
Developing Cardiac Rehabilitation in Vietnam Dr Juliette Hussey School of Medicine Trinity College Dublin Ireland.
FHI’s Global ART Program: Today's snapshot and tomorrow's vision 10 August 2010 Kwasi Torpey, MD, PhD, MPH Regional Senior Technical Advisor, FHI 8 th.
Remarks HIV and CVD Integration Peter Lamptey. Rationale for CVD/HIV Integration HIV and CVD synergies – HIV effects on CVD risk factors – HAART effects.
VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.
Adult Hypertension Survey Results Mercy Medical Group, Inc. Alan R. Ertle, MD, MPH, MBA Friday, January 09, 2015.
Metabolic Syndrome in HIV- Infected Patients from MTCT-Plus, Thai Outpatient Population J. JANTARAPAKDE1,2,*, C. CHATURAWIT1,2, S. PENGNONYANG1,2, W. PIMA1,
CRDAC Questions June 15, 2005 Antihypertensive drugs, with few exceptions, have no outcome claim in their labeling. This is inconsistent with their approval.
HvC Comparative Effectiveness Project Groups 5 and 6
Surviving Childhood Cancer: What’s Next? Trisha Kinnard PAS 646.
HIV and Non-Communicable Diseases Pre-Conference, July 2011 Sinata Koulla-Shiro MOH, Cameroon HIV and Non-communicable Diseases Pre-Conference, July.
Dr. I. Selvaraj Indian Railways Medical Service B.Sc., M.B.B.S., M.D.,D.P.H., D.I.H., PGCHFW ( NIHFW,New Delhi)., Life member of Indian Association of.
Double Jeopardy. International Diabetes Federation Diabetes State of raised blood glucose (hyperglycaemia) associated with premature mortality Pancreas.
MIAMI: MIRECC Initiative on Antipsychotic Management Improvement Metabolic Monitoring and Management of Antipsychotic Medication.
Using QOF and Service Specifications to meet HI Needs Rachel Foskett-Tharby.
Whole person care. Growth of specialist services Coexisting conditions Focus of secondary care, benefits of community care providers How are we doing?
CHAPTER 7: Obesity in Women. Introduction 68% of U.S. population is overweight or obese. Resulting medical and psychosocial difficulties can be debilitating.
The Poor Health Status of Consumers of Mental Health Care: Prevalence, Quality of Care and Cost for Persons with SMI and Diabetes Brenda Harvey, Commissioner.
Cholesterol-lowering effects of a stanol- ester containing low-fat margarine used in conjunction with a strict lipid-lowering diet Andersson A et al. Eur.
South Tyneside Joint Strategic Needs Assessment Refresh East Shields Community Area Forum Alice Wiseman Children’s Commissioning Lead – South Tyneside.
Linkages between CDs & NCDs: The African context Dr Frank J Mwangemi ICASA 2011: 5 th December 2011 Addis Ababa, Ethiopia.
Global health in the news h/study-shows-spread-of-cigarettes-in- china.html?ref=health&_r=0.
T HREE STRIKES IS ENOUGH Karalyn J Huxhagen B Pharm FPS AACPA Cardiovascular Health Sleep Apnoea Diabetes.
SECONDARY PREVENTION IN HEART DISEASE CATHY QUICK AUBURN UNIVERSITY/AUBURN MONTGOMERY EBP III.
Chapter Metabolic Syndrome Peterson and Gordon C H A P T E R.
Cardiovascular Risk: A global perspective
Nick Banatvala & Pascal Bovet
Human Immunodeficiency Virus
Prevention Diabetes.
World Health Organization
The Poor Health Status of Consumers of Mental Health Care: Prevalence, Quality of Care and Cost for Persons with SMI and Diabetes Brenda Harvey, Commissioner.
ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.
Bayard Roberts ECOHOST – The Centre for Health and Social Change
Diabetic Dyslipidemia in Practice
Repeat fasting lipid profile to confirm in 1-2 weeks
Overview of Disparities
Section VIII. Ambulatory BP Measurement
Prevention Diabetes Dr Abir Youssef 29/11/2018.
Section VII: Summary New focus on treating hypertension beyond the numbers Content Points: In view of current clinical understanding of the link between.
Type 2 diabetes: Overlap of clinical conditions
Healthy With HIV.
THE ELDERLY POPULATION
Dr Timothy Armstrong Coordinator
TECHNOLOGY DEVELOPMENT COMPANY INTRODUCTION
Summary Content Points:
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

HIV and Non-communicable Diseases Pre-Conference, July 15-16, 2011, Rome Gaps in Knowledge, and Future Research Priorities in LMIC NCD Risk in PLWH 1.What is the level of risk of NCD (such as elevated blood pressure, dyslipidemia, cardiomyopathy and disordered glucose metabolism) in PLWH in LMIC as a result: a)NCD risk factors such as smoking b)HIV disease c)HAART 2.Is there a difference in NCD complications in PLWH in children, and between men and women? e.g. high cardiac mortality in children with maternally- acquired HIV. 3.Is the NCD risk in PLWH high enough to warrant routine monitoring in HIV care and treatment programs? 4.What is the clinical significance of impaired glucose tolerance in the patients with HIV? Should it be treated, and how?

HIV and Non-communicable Diseases Pre-Conference, July 15-16, 2011, Rome Gaps in Knowledge, and Future Research Priorities in LMIC NCD Risk and HAART 1.Should HAART protocol be modified in PLWH with NCD risk factors in LMIC? e.g. AZT and Stavudine may affect myocardial function. 2.Are NCD risks higher in LMIC as a result of intermittent HAART therapy because of poor adherence (intermittent therapy has been shown to increase CVD risk - RCT) Monitoring of NCD Risk in PLWH 1.What are the recommended metabolic and anthropometric monitoring recommended for PLWH on care and PLWH on HAART e.g. blood lipids, blood glucose, blood pressure, BMI, visceral fat gain, loss of subcutaneous fat

HIV and Non-communicable Diseases Pre-Conference, July 15-16, 2011, Rome Gaps in Knowledge, and Future Research Priorities in LMIC NCD and HAART Drug Interactions 1.What are the possible drug interactions of NCD therapy with HAART – e.g. lipid-lowering drugs, anti-hypertensive agents, etc.? NCD/HIV Integration research 1.What is the appropriate integration target population? a)Use HIV platform to integrate for general population b)Use HIV platform to integrate for all PLWH c)Use HIV platform to integrate for only PLWH at risk of NCD 2.What are the most feasible cost-effective integration models without reducing the effectiveness of the component HIV and NCD programs?